Qualitox Laboratories, LLC

Qualitox Laboratories, LLC was paid $16.94M by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#10 of 95

Median peer was paid$153K

This provider vs. median111×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	73,697	$334K
2019	108,476	$626K
2020	147,288	$1.83M
2021	164,780	$3.09M
2022	197,605	$3.79M
2023	198,578	$3.80M
2024incomplete	156,093	$3.47M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	22%	75,879	44,132	$3.65M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	17%	75,631	42,891	$2.85M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	11%	35,684	27,559	$1.87M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.1%	116,781	65,028	$1.54M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	9.1%	61,485	33,230	$1.54M
87631		3.3%	21,078	15,917	$567K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.7%	53,186	32,453	$461K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.4%	29,299	17,497	$411K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.3%	21,731	13,668	$394K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.0%	18,499	12,015	$331K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	1.6%	9,877	7,106	$278K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	1.2%	2,402	1,937	$200K

165 more codes

87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	1.2%	2,066	$195K
87581		1.1%	22,917	$180K
87640		1.0%	26,106	$176K
87541		1.0%	21,374	$172K
87481		<1%	7,027	$147K
87529		<1%	4,252	$70K
80365		<1%	14,442	$62K
80372		<1%	14,340	$62K
80366		<1%	14,042	$61K
80358		<1%	14,219	$60K
80353		<1%	14,506	$59K
80355		<1%	14,082	$59K
80368		<1%	13,102	$59K
80354		<1%	14,564	$58K
80321		<1%	13,535	$58K
80323		<1%	11,996	$56K
80360		<1%	14,439	$55K
80356		<1%	14,452	$55K
80359		<1%	13,578	$55K
80349		<1%	13,074	$54K
80361		<1%	9,302	$49K
87653		<1%	9,621	$49K
80338		<1%	10,574	$48K
80357		<1%	10,208	$47K
87486		<1%	5,179	$45K
83992		<1%	9,494	$42K
80348		<1%	9,718	$40K
80373		<1%	9,383	$39K
80370		<1%	7,518	$38K
80347		<1%	7,187	$37K
80325		<1%	9,025	$36K
80363		<1%	7,115	$35K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	4,342	$35K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	4,305	$34K
80333		<1%	7,113	$31K
87563		<1%	3,979	$31K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	3,672	$29K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	4,779	$29K
80050	General health panel	<1%	4,587	$29K
80337		<1%	5,323	$28K
87511		<1%	3,919	$24K
80061	Lipid panel	<1%	6,983	$19K
80324		<1%	5,177	$18K
80362		<1%	6,568	$18K
80346		<1%	3,023	$18K
80053	Comprehensive metabolic panel	<1%	6,578	$17K
80332		<1%	3,522	$16K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	3,471	$15K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	7,594	$13K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	612	$13K
80364		<1%	2,319	$13K
83036	Hemoglobin; glycosylated (A1C)	<1%	6,212	$12K
87500		<1%	1,571	$11K
87641		<1%	1,546	$10K
84481		<1%	2,262	$9K
87150		<1%	293	$8K
82607		<1%	2,801	$8K
84443	Thyroid stimulating hormone (TSH)	<1%	2,385	$7K
87551		<1%	852	$7K
36415	Collection of venous blood by venipuncture	<1%	5,807	$6K
84439		<1%	2,991	$6K
80342		<1%	1,871	$5K
80336		<1%	1,992	$4K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,235	$4K
82746		<1%	1,392	$4K
81514		<1%	271	$4K
81230		<1%	66	$4K
81231		<1%	115	$4K
82728		<1%	1,247	$4K
87902		<1%	60	$4K
87505		<1%	213	$3K
82670		<1%	437	$3K
80345		<1%	588	$2K
83735		<1%	1,410	$2K
87999		<1%	90	$2K
84403		<1%	363	$2K
83001		<1%	369	$1K
84146		<1%	334	$1K
87181		<1%	263	$1K
83002		<1%	350	$1K
80164		<1%	169	$1K
87522	Neg quan hep c or qual rna	<1%	229	$1K
84144		<1%	268	$1K
86780		<1%	305	$992.02
84702		<1%	334	$906.23
87184		<1%	99	$881.37
86703		<1%	317	$818.52
84402		<1%	156	$775.32
87109		<1%	98	$769.26
87086	Culture, bacterial; quantitative colony count, urine	<1%	763	$685.83
81226		<1%	115	$676.36
81479	Unlisted molecular pathology procedure	<1%	92	$675.00
83970		<1%	123	$674.04
86803		<1%	239	$649.59
82652		<1%	78	$637.06
87046		<1%	98	$603.19
80074		<1%	70	$582.57
87186		<1%	213	$563.14
80369		<1%	141	$530.38
81001		<1%	836	$514.13
81355		<1%	13	$509.63
80299		<1%	107	$499.05
80339		<1%	107	$485.17
81225		<1%	114	$437.04
84466		<1%	188	$427.39
84153		<1%	90	$382.68
81241		<1%	12	$323.90
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	125	$321.23
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	264	$314.88
86140		<1%	570	$314.23
81240		<1%	12	$299.40
84480		<1%	162	$287.50
87076		<1%	258	$279.57
84550		<1%	294	$279.39
87340		<1%	258	$256.31
86704		<1%	122	$234.08
84436		<1%	156	$232.42
87507		<1%	18	$190.40
83690		<1%	358	$176.74
84100		<1%	210	$169.71
86762		<1%	130	$158.18
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	2,050	$151.35
86708		<1%	71	$145.21
81003		<1%	257	$137.54
82570		<1%	98	$135.75
82977		<1%	67	$129.60
85652		<1%	282	$128.76
82248		<1%	115	$123.93
80170		<1%	101	$121.36
86592		<1%	274	$111.61
86431		<1%	186	$102.84
83540		<1%	118	$97.22
82150		<1%	274	$89.99
83721		<1%	229	$88.41
86709		<1%	45	$86.92
82533		<1%	122	$84.73
85027		<1%	61	$83.06
84410		<1%	16	$80.00
83525		<1%	63	$49.64
85610		<1%	22	$48.66
82542		<1%	107	$47.22
82627		<1%	18	$41.72
80076		<1%	50	$41.09
84703		<1%	13	$40.79
84270		<1%	18	$40.76
84080		<1%	27	$39.89
86850		<1%	64	$31.23
87070		<1%	19	$25.85
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	21	$22.96
86706		<1%	36	$17.90
86900		<1%	63	$12.16
82310		<1%	21	$11.35
82040		<1%	20	$10.88
82550		<1%	45	$9.38
84520		<1%	16	$8.70
82947		<1%	31	$6.27
86038		<1%	12	$4.99
86901		<1%	16	$2.44
82378		0%	38	$0.00
81227		0%	49	$0.00
80184		0%	451	$0.00
87081		0%	97	$0.00
86317		0%	13	$0.00
81291		0%	61	$0.00
80326		0%	228	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSTRAHAN, ALEX (CEO/PRESIDENT)